Stockreport

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026  New Data Sho [Read more]